Kuros and Synthes Inc. announce license and development agreement
Kuros Biosurgery AG has signed a license and development agreement with Synthes, Inc.. Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros’ synthetic matrix technology in certain fields.
Commenting on today’s announcement, Mr. Didier Cowling, CEO of Kuros, said: “We are delighted to have signed this deal related to our synthetic matrix technologies with Synthes. Partnering our products with leading marketing partners is a key element of Kuros’ strategy and we are looking forward to a productive working relationship with Synthes”.
Michel Orsinger, President and CEO of Synthes, commented on the partnership: "The Kuros partnership is an important addition to Synthes goal of being a total solutions provider for our customers. The partnership will strengthen both Kuros and Synthes commitment to develop patient focused clinical solutions."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Ares Genetics GmbH - Wien, Austria

Operation of ancient biological clock uncovered
Research on how plants transport sugars could be of critical importance in era of global warming

Last-line antibiotics are failing
GNA Biosolutions completes € 6 million financing round - Prepares for market entry with fast diagnostic instruments for hospital bugs
BASF Fine Chemicals Switzerland SA and BASF Orgamol Pharma Solutions SA merger announced - Company renamed BASF Pharma (Evionnaz) SA
